Dendrimer-induced leukocyte procoagulant activity depends on particle size and surface charge

Nanomedicine

Volumn 7, Issue 2, 2012, Pages 245-256

  Dobrovolskaia, Marina A ^a   Patri, Anil K ^a   Potter, Timothy M ^a   Rodriguez, Jamie C ^a   Hall, Jennifer B ^a   McNeil, Scott E ^a  

^a SAIC FREDERICK INC   (United States)

Author keywords

coagulopathy; disseminated intravascular coagulation; leukocytes; PAMAM dendrimers; procoagulant activity; thrombosis

Indexed keywords

CATION; DENDRIMER; DOXORUBICIN; POLYAMIDOAMINE; PROCOAGULANT;

ARTICLE; CHEMICAL STRUCTURE; CONTROLLED STUDY; DENSITY; HUMAN; HUMAN CELL; IN VITRO STUDY; LEUKEMIA CELL; LEUKOCYTE; PARTICLE SIZE; PERIPHERAL BLOOD MONONUCLEAR CELL; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; PROTEIN SYNTHESIS; RNA SYNTHESIS; SURFACE CHARGE;

BLOOD COAGULATION FACTORS; CELLS, CULTURED; DENDRIMERS; HUMANS; LEUKOCYTES; NANOCAPSULES; PARTICLE SIZE; STATIC ELECTRICITY;

EID: 84857526883     PISSN: 17435889     EISSN: 17486963     Source Type: Journal    
DOI: 10.2217/nnm.11.105     Document Type: Article

References (56)

1. Barbui T, Falanga A. Disseminated intravascular coagulation in acute leukemia. Semin. Thromb. Hemost. 27(6), 593-604 (2001).
2. Franchini M, Dario Di Minno MN, Coppola A. Disseminated intravascular coagulation in hematologic malignancies. Semin. Thromb. Hemost. 36(4), 388-403 (2010).
3. Higuchi T, Toyama D, Hirota Y, et al. Disseminated intravascular coagulation complicating acute lymphoblastic leukemia: A study of childhood and adult cases. Leuk. Lymphoma 46(8), 1169-1176 (2005).
4. Levi M. Cancer and DIC. Haemostasis 31(Suppl. 1), 47-48 (2001).
5. Levi M. Disseminated intravascular coagulation in cancer patients. Best Pract. Res. Clin. Haematol. 22(1), 129-136 (2009).
6. Khemani RG, Bart RD, Alonzo TA, et al. Disseminated intravascular coagulation score is associated with mortality for children with shock. Intensive Care Med. 35(2), 327-333 (2009).
7. Lando PA, Edgington TS. Lymphoid procoagulant response to bacterial endotoxin in the rat. Infect. Immun. 50(3), 660-666 (1985).
8. Oh D, Jang MJ, Lee SJ, et al. Evaluation of modified non-overt DIC criteria on the prediction of poor outcome in patients with sepsis. Thromb. Res. 126(1), 18-23 (2010).
9. Slofstra SH, ten Cate H, Spek CA. Low dose endotoxin priming is accountable for coagulation abnormalities and organ damage observed in the Shwartzman reaction. A comparison between a single-dose endotoxemia model and a double-hit endotoxin-induced Shwartzman reaction. Thromb. J. 4, 13 (2006).
10. Uchiumi H, Matsushima T, Yamane A, et al. Prevalence and clinical characteristics of acute myeloid leukemia associated with disseminated intravascular coagulation. Int J. Hematol. 86(2), 137-142 (2007).
11. Napoleone E, Zurlo F, Latella MC, et al. Paclitaxel downregulates tissue factor in cancer and host tumour-associated cells. Eur. J. Cancer 45(3), 470-477 (2009).
12. Swystun LL, Shin LY, Beaudin S, Liaw PC. Chemotherapeutic agents doxorubicin and epirubicin induce a procoagulant phenotype on endothelial cells and blood monocytes. J. Thromb. Haemost. 7(4), 619-626 (2009).
13. Fibach E, Treves A, Korenberg A, Rachmilewitz EA. In vitro generation of procoagulant activity by leukemic promyelocytes in response to cytotoxic drugs. Am. J. Hematol. 20(3), 257-265 (1985).
14. Gralnick HR, Abrell E. Studies of the procoagulant and fibrinolytic activity of promyelocytes in acute promyelocytic leukaemia. Br. J. Haematol. 24(1), 89-99 (1973).
15. Kwaan HC, Wang J, Boggio LN. Abnormalities in hemostasis in acute promyelocytic leukemia. Hematol. Oncol. 20(1), 33-41 (2002).
16. Stein E, McMahon B, Kwaan H, et al. The coagulopathy of acute promyelocytic leukaemia revisited. Best Pract. Res. Clin. Haematol. 22(1), 153-163 (2009).
17. ten Cate H, Falanga A. Overview of the postulated mechanisms linking cancer and thrombosis. Pathophysiol. Haemost. Thromb. 36(3-4), 122-130 (2008).
18. ten Cate H, Falanga A. The pathophysiology of cancer and thrombosis. Summary and conclusions. Pathophysiol. Haemost. Thromb. 36(3-4), 212-214 (2008).
19. Walsh J, Wheeler HR, Geczy CL. Modulation of tissue factor on human monocytes by cisplatin and adriamycin. Br. J. Haematol. 81(4), 480-488 (1992).
20. Wheeler HR, Geczy CL. Induction of macrophage procoagulant expression by cisplatin, daunorubicin and doxorubicin. Int. J. Cancer 46(4), 626-632 (1990).
21. Bach R, Rifkin DB. Expression of tissue factor procoagulant activity: regulation by cytosolic calcium. Proc. Natl Acad. Sci. USA 87(18), 6995-6999 (1990).
22. Hiller E, Saal JG, Ostendorf P, Griffiths GW. The procoagulant activity of human granulocytes, lymphocytes and monocytes stimulated by endotoxin. Coagulation and electron microscopic studies. Klin. Wochenschr. 55(15), 751-757 (1977).
23. Marx V. Poised to branch out. Nat. Biotechnol. 26(7), 729-732 (2008).
24. McCarthy TD, Karellas P, Henderson SA, et al. Dendrimers as drugs: discovery and preclinical and clinical development of dendrimer-based microbicides for HIV and STI prevention. Mol. Pharm. 2(4), 312-318 (2005).
25. Biricova V, Laznickova A. Dendrimers: Analytical characterization and applications. Bioorg. Chem. 37(6), 185-192 (2009).
26. Chen HT, Neerman MF, Parrish AR, Simanek EE. Cytotoxicity, hemolysis, and acute in vivo toxicity of dendrimers based on melamine, candidate vehicles for drug delivery. J. Am. Chem. Soc. 126(32), 10044-10048 (2004).
27. Domanski DM, Klajnert B, Bryszewska M. Influence of PAMAM dendrimers on human red blood cells. Bioelectrochemistry. 63(1-2), 189-191 (2004).
28. Duncan R, Izzo L. Dendrimer biocompatibility and toxicity. Adv. Drug Deliv. Rev. 57(15), 2215-2237 (2005).
29. Han MH, Chen J, Wang J, Chen SL, Wang XT. Blood compatibility of polyamidoamine dendrimers and erythrocyte protection. J. Biomed. Nanotechnol. 6(1), 82-92 (2010).
30. US FDA CDER, CBER, CDRH, CVM. Guideline on validation of the Limulus amebocyte lysate test as an end-product endotoxin test for humanand animal parenteral drugs, biological products, and medical devices. CDER, CBER, CDRH, CVM, Rockville, MD, USA 20857 (1987).
31. USP 30 NF 25. Bacterial endotoxins test. 85 (2007).
32. Sato H, Konishi Y, Tanaka H, Takahashi O, Tanaka T. Annexin V inhibits lipopolysaccharide-induced procoagulant activity on human monocytes. Thromb. Res. 114(1), 45-49 (2004).
33. Hall JB, Dobrovolskaia MA, Patri AK, McNeil SE. Characterization of nanoparticles for therapeutics. Nanomedicine (Lond). 2(6), 789-803 (2007).
34. Tomalia D. The dendritic state. Materials Today. March, 34-46 (2005).
35. Kerk N, Strozyk EA, Poppelmann B, Schneider SW. The mechanism of melanoma-associated thrombin activity and von Willebrand factor release from endothelial cells. J. Invest. Dermatol. 130(9), 2259-2268 (2010).
36. Bach RR. Tissue factor encryption. Arterioscler. Thromb. Vasc. Biol. 26(3), 456-461 (2006).
37. Mukherjee SP, Davoren M, Byrne HJ. In vitro mammalian cytotoxicological study of PAMAM dendrimers -towards quantitative structure activity relationships. Toxicol. In vitro. 24(1), 169-177 (2010).
38. Tomalia DA. In quest of a systematic framework for unifying and defining nanoscience. J Nanopart. Res. 11(6), 1251-1310 (2009).
39. Hong S, Bielinska AU, Mecke A, et al. Interaction of poly(amidoamine) dendrimers with supported lipid bilayers and cells: hole formation and the relation to transport. Bioconjug. Chem. 15(4), 774-782 (2004).
40. Hong S, Leroueil PR, Janus EK, et al. Interaction of polycationic polymers with supported lipid bilayers and cells: nanoscale hole formation and enhanced membrane permeability. Bioconjug. Chem. 17(3), 728-734 (2006).
41. Kelly CV, Leroueil PR, Orr BG, Banaszak Holl MM, Andricioaei I. Poly(amidoamine) dendrimers on lipid bilayers II: effects of bilayer phase and dendrimer termination. J. Phys. Chem. B. 112(31), 9346-9353 (2008).
42. Leroueil PR, Berry SA, Duthie K, et al. Wide varieties of cationic nanoparticles induce defects in supported lipid bilayers. Nano Lett. 8(2), 420-424 (2008).
43. Dobrovolskaia MA, Patri AK, Zheng J, et al. Interaction of colloidal gold nanoparticles with human blood: effects on particle size and analysis of plasma protein binding profiles. Nanomedicine. 5(2), 106-117 (2009).
44. Jones CF, Grainger DW. In vitro assessments of nanomaterial toxicity. Adv. Drug Deliv. Rev. 61(6), 438-456 (2009).
45. DeLuca T., Kaszuba M., Mattison K. Optimizing silicon emulsion stability using zeta potential. American Laboratory News. June/July, 1-3 (2006).
46. Using zeta potential to assess protein adsorption to surfactant coated latex. Malvern Instruments zeta sizer nano application note. MRK707-01, 1-3 (2001).
47. Zeta potential: An introduction in 30 minutes. Malvern Instruments zeta sizer nano series technical note. MRK654-01, 1-6 (2001).
48. Dobrovolskaia MA, Neun BW, Clogston JD, et al. Ambiguities in applying traditional Limulus amebocyte lysate tests to quantify endotoxin in nanoparticle formulations. Nanomedicine (Lond). 5(4), 555-562 (2010).
49. Barbui T, Falanga A. Disseminated intravascular coagulation in acute leukemia. Semin. Thromb. Hemost. 27(6), 593-604 (2001).
50. Vallhov H, Qin J, Johansson SM, et al. The importance of an endotoxin-free environment during the production of nanoparticles used in medical applications. Nano Lett. 6(8), 1682-1686 (2006).
51. Schneider P, Van Dreden P, Rousseau A, et al. Increased levels of tissue factor activity and procoagulant phospholipids during treatment of children with acute lymphoblastic leukaemia. Br. J. Haematol. 148(4), 582-592 (2010).
52. Inoue K. Promoting effects of nanoparticles/ materials on sensitive lung inflammatory diseases. Environ. Health Prev. Med. 16(3), 139-143 (2011).
53. Inoue K, Takano H. Aggravating impact of nanoparticles on immune-mediated pulmonary inflammation. ScientificWorldJournal 11, 382-390 (2011).
54. Shi Y, Yadav S, Wang F, Wang H. Endotoxin promotes adverse effects of amorphous silica nanoparticles on lung epithelial cells in vitro. J. Toxicol. Environ. Health A. 73(11), 748-756 (2010).
55. Mukherjee SP, Lyng FM, Garcia A, Davoren M, Byrne HJ. Mechanistic studies of in vitro cytotoxicity of poly(amidoamine) dendrimers in mammalian cells. Toxicol. Appl. Pharmacol. 248(3), 259-268 (2010).
56. Choi YS, Cho TS, Kim JM, Han SW, Kim SK. Amine terminated G-6 PAMAM dendrimer and its interaction with DNA probed by Hoechst 33258. Biophys. Chem. 121(2), 1